This is a Imfinzi news story, published by Yahoo, that relates primarily to AstraZeneca news.
For more Imfinzi news, you can click here:
more Imfinzi newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster cancer drug Imfinzi. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest chemotherapy news, chemotherapy drugs carboplatin news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
specific endometrial cancer patientsReuters
•78% Informative
AstraZeneca 's blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. Drug is approved for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) The approval came after a late stage trial showed the drug reduced the risk of disease progression or death by 58% in specific endometrian cancer patients, compared to chemotherapy alone.
VR Score
88
Informative language
98
Neutral language
7
Article tone
formal
Language
English
Language complexity
84
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links